Worthington & Caron, PC is proud to be lead sponsor of the
The 7th International Mesothelioma Symposium on Lung-Sparing Therapies
for Malignant Pleural Mesothelioma where international experts will meet to discuss the latest treatment
options for mesothelioma.
The 7th International Symposium will be held Saturday, September 30th at
the UCLA Meyer & Renee Luskin Conference Center in Los Angeles, California.
Course Chair Dr. Robert Cameron has over 30 years of experience treating
patients with malignant pleural mesothelioma. He has played a vital role
in the development of lung-sparing treatments including the pleurectomy/decortication
surgery and a number of adjuvant therapies. Dr. Cameron serves as Director of the
Comprehensive Mesothelioma Programs at UCLA Medical Center and the
West Los Angeles VA Medical Center. He also serves as Scientific Advisor at the
Pacific Mesothelioma Center.
Dr. Cameron will be joined by leading mesothelioma experts who will highlight
recent advancements in mesothelioma treatment and cutting-edge research.
All physicians and nurses attending will receive continuing medical education
(CME) course credit.
*Patients and families are welcome and encouraged to attend.
For more information, and to register, click
here.
Presentations and Discussions:
-
Immune Checkpoint Blockade in Malignant Mesothelioma:
- Luana Calabrò, MD, Medical Oncology and Immunotherapy, University
Hospital of Siena, Siena, Italy.
-
The Potato in the Tailpipe! Disabling Mitochondrial Peroxide Metabolism
As An Effective Therapeutic Approach for MPM:
- Brian Cunniff, PhD., Faculty Scientist, Department of Pathology, Vermont
Cancer Center, University of Vermont College of Medicine.
-
Trans Arterial Chemo Perfusion:
- Jacques P. Fontaine M.D, Thoracic Surgeon, Associate Professor, University
of South Florida, Moffitt Cancer Center.
-
Combining Angiogenesis Inhibition with Chemotherapy, Who, How and What's Next?:
- Anna Nowak, MBBS, FRACP, PhD., Professor, Faculty of Medicine, University
of Western Australia.
-
Inflammasome Modulation by Chemotherapeutics in Mesothelioma: Is This a
New Possibility?:
- Arti Shukla, PhD, Associate Professor, Departments of Pathology and Medicine,
Larner College of Medicine, University of Vermont, Burlington, Vermont.
-
Targeting the Epigenome in Malignant Pleural Mesothelioma:
- David S. Schrump, MD, MBA, FACS, Senior Investigator and Surgical Chief
CCR/NCI, Bethesda, MD.
-
Recent Findings on Mesothelioma and BAP1:
- Haining Yang, MD, PhD., Professor, Cancer Biology Program, University of
Hawaii Cancer Center, Honolulu, Hawaii.
-
Surgery for Mesothelioma: Is There a Future?:
- Robert B. Cameron, MD, FACS
-
Intracavitary Therapeutics for Pleural Malignancies:
-
Engineering Mesenchymal Stem Cells for Immunotherapy of Mesothelioma:
- Robert B. Cameron, MD, FACS
-
The Benefits of a Mesothelioma Caregivers Support Group:
- Lien Hua-Feng, RN, MSN, NP-C
-
Resources for Research-Student Internship Program:
Related Posts: